



DATE: June 17, 2004 SHEET 1 of 2

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Modified) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. 7023US02
SERIAL NO. 10/743,954

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98 (b))

APPLICANT
R. Kurukulasuriya et al.
FILING DATE December 23, 2003
GROUP 1614 1626

U.S.PATENT DOCUMENTS

| EXAMINER INITIAL | | PATENT NUMBER | | | | | | ISSUE DATE | PATENTEE | CLASS | SUB CLASS | FILING DATE |
|------------------|----|---------------|---|---|---|---|---|------------|------------|-------------------|-----------|-------------|
| NG | A1 | 5 | 7 | 7 | 6 | 9 | 5 | 4 | 07/07/98 | de Laszlo, et al. | — | — |
| NG | A2 | 5 | 8 | 8 | 0 | 1 | 3 | 9 | 03/09/99 | Chang | — | — |
| NG | A3 | 6 | 2 | 1 | 8 | 4 | 3 | 1 | 04/17/2001 | Schoen, et al. | — | — |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

| | | DOCUMENT NUMBER | | | | | | PUBLI-CATION DATE | COUNTRY OR PATENT OFFICE | CLASS | SUB CLASS | TRANSLATION YES NO |
|----|-----|-----------------|---|---|---|---|---|-------------------|--------------------------|-------|-----------|--------------------|
| NG | B1 | 9 | 7 | 1 | 6 | 4 | 4 | 2 | 09.05.97 | WO | — | — |
| NG | B2 | 9 | 8 | 2 | 1 | 9 | 5 | 7 | 28.05.98 | WO | — | — |
| NG | B3 | 9 | 8 | 2 | 2 | 1 | 0 | 8 | 28.05.98 | WO | — | — |
| NG | B4 | 9 | 8 | 2 | 2 | 1 | 0 | 9 | 28.05.98 | WO | — | — |
| NG | B5 | 9 | 9 | 0 | 1 | 4 | 2 | 3 | 14.01.99 | WO | — | — |
| NG | B6 | 0 | 0 | 3 | 9 | 0 | 8 | 8 | 06.07.2000 | WO | — | — |
| NG | B7 | 0 | 0 | 6 | 9 | 8 | 1 | 0 | 23.11.2000 | WO | — | — |
| NG | B8 | 0 | 2 | 0 | 0 | 6 | 1 | 2 | 03.01.2002 | WO | — | — |
| NG | B9 | 0 | 2 | 4 | 0 | 4 | 4 | 4 | 23.05.2002 | WO | — | — |
| NG | B10 | 0 | 2 | 4 | 0 | 4 | 4 | 5 | 23.05.2002 | WO | — | — |
| NG | B11 | 0 | 2 | 4 | 0 | 4 | 4 | 6 | 23.05.2002 | WO | — | — |

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

| | | |
|------|-----|---|
| NG | C1 | Ahrén, B., & Larsson, H., "Impaired glucose tolerance (IGT) is associated with reduced insulin-induced suppression of glucagon concentrations", <i>Diabetologia</i> , 44:1998-2003 (2001) |
| NG | C2 | Baron, A. C., et al., "Role of Hyperglucagonemia in Maintenance of Increased Rates of Hepatic Glucose Output in Type II Diabetics", <i>Diabetes</i> , 36:274-283 (1987) |
| NG | C3 | Brand, C. L., et al., "Evidence for a Major Role for Glucagon in Regulation of Plasma Glucose In Conscious, Nondiabetic, and Alloxan-Induced Diabetic Rabbits", <i>Diabetes</i> , 46:1076-1083 (1996) |
| NG | C4 | Brand, C. L., et al., "Immunoneutralization of endogenous glucagon with monoclonal glucagon antibody normalizes hyperglycaemia in moderately streptozotocin-diabetic rats", <i>Diabetologia</i> , 37:985-993 (1994) |
| NG | C5 | Brand, C. L., et al., <i>American Diabetes Assn Poster Session in San Antonio, TX</i> , pgs. A81 & A428 (2000) |
| NG | C6 | Cascieri, M. A., et al., "Characterization of a Novel, Non-peptidyl Antagonist of the Human Glucagon Receptor", <i>The Journ. of Biol. Chem.</i> 1999, 274:8694-8697 (1999) |
| ✓ NG | C7 | Chang, L. L., et al., "Substituted Imidazoles as Glucagon Receptor Antagonists", <i>Biorganic & Med. Chem. Ltrs.</i> , 11:2549-2553 (2001) |
| NG | C8 | de Feo, P., et al., "Contribution of cortisol to glucose counterregulation in humans", <i>Am. J. Physiol.</i> 257:E35-E42 (1989) |
| NG | C9 | de Laszlo, S. E., et al., "POTENT, ORALLY ABSORBED GLUCAGON RECEPTOR ANTAGONISTS", <i>Biorganic & Med. Chem. Ltrs.</i> , 9:641-646 |
| NG | C10 | DeFronzo, R. A., "Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes", <i>Diabetes Reviews</i> , 5(3):177-269 (1997) |

S.O.O

| | | |
|-----------|-----|--|
| <i>NG</i> | C11 | Dinneen, S., et al., "Metabolic Effects of the Nocturnal Rise in Cortisol on Carbohydrate Metabolism in Normal Humans", <i>J. Clin. Invest.</i> , 92:2283-2290 (1993) |
| <i>NG</i> | C12 | Dobbs, R., et al., "Glucagon: Role in the Hyperglycemia of Diabetes Mellitus", <i>Science</i> , 187:544-547 (1975) |
| <i>NG</i> | C13 | Friedman et al., <i>J. Biol. Chem.</i> , 272(50):31475-31481 (1997) |
| <i>NB</i> | C14 | Guillon, J., et al., "Synthesis of new pyrrolo[1,2-a]quinoxalines: potential non-peptide glucagon receptor antagonists", <i>Eur. J. Med. Chem.</i> , 33:293-308 (1998) |
| <i>NG</i> | C15 | Ladouceur, G. H., et al., "4-Phenylpyridine glucagon receptor antagonists: synthetic approaches to the sterically hindered chiral hydroxy group", <i>Tetrahedron Ltrs.</i> , 43:4455-4458 (2002) |
| <i>NG</i> | C16 | Ladouceur, G. H., et al., "Discovery of 5-Hydroxyalkyl-4-phenylpyridines as a New Class of Glucagon Receptor Antagonists", <i>Bioorganic & Med. Chem. Ltrs.</i> , 12:461-464 (2002) |
| <i>NG</i> | C17 | Langley et al., <i>Am. J. Physiol.</i> 259(Regulatory Integrative Comp. Physiol. 28):R539-R544 (1990) |
| <i>NP</i> | C18 | Ling, A., et al., "Human Glucagon Receptor Antagonists Based on Alkylidene Hydrazides", <i>Bioorganic & Med. Chem. Ltrs.</i> , 12:663-666 (2002) |
| <i>NG</i> | C19 | Ling, A., et al., "Identification of Alkylidene Hydrazides as Glucagon Receptor Antagonists", <i>J. Med. Chem.</i> , 44:3141-3149 (2001) |
| <i>NG</i> | C20 | Madsen, P., et al., "Discovery and Structure-Activity Relationship of the First Non-Peptide Competitive Human Glucagon Receptor Antagonists", <i>J. Med. Chem.</i> , 41:5150-5157 (1998) |
| <i>NG</i> | C21 | Magnusson, I., et al., "Increased Rate of Gluconeogenesis in Type II Diabetes Mellitus A 13C Nuclear Magnetic Resonance Study", <i>J. Clin. Invest.</i> , 90:1323-1327 (1992) |
| <i>NP</i> | C22 | Parker, J. C., et al., "Effects of Skyrin, a Receptor-Selective Glucagon Antagonist, in Rat and Human Hepatocytes", <i>Diabetes</i> , 49:2079-2086 (2000) |
| <i>NG</i> | C23 | Petersen K. F. & Sullivan, J. T., "Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans", <i>Diabetologia</i> , 44:2018-2024 |
| <i>NG</i> | C24 | Post, S. R., et al., "Mechanism of Action of des-His ¹ [Glu ²]glucagon amide, a peptide antagonist of the glucagon receptor system", <i>Proc. Natl. Acad. Sci. USA</i> , 90:1662-1666 (1993) |
| <i>NG</i> | C25 | Reaven, G. M., et al., "Documentation of Hyperglucagonemia Throughout the Day in Nonobese and Obese Patients with Noninsulin-Dependent Diabetes Mellitus", <i>J. of Clin. Endocrin. & Metab.</i> , 64:106-110 (1987) |
| <i>NG</i> | C26 | Rizza, R., et al., "Effect of Intermittent Endogenous Hyperglucagonemia on Glucose Homeostasis in Normal and Diabetic Man", <i>J. Clin. Invest.</i> , 63:1119-1123 (1979) |
| <i>NG</i> | C27 | Rooney, D. P., et al., "The Effect of Cortisol on Glucose/Glucose-6-Phosphate Cycle Activity and Insulin Action", <i>J. Clin. Endocrin. & Metabol.</i> , 77:1180-1183 (1994) |
| <i>NG</i> | C28 | Shah, P., et al., "Impact of lack of suppression of glucagon on glucose tolerance in humans", <i>Am. J. Physiol.</i> , 277:E283-E290 (1999) |
| <i>NG</i> | C29 | Shah, P., et al., "Lack of Suppression of Glucagon Contribut4s to Postprandial Hyperglycemia in Subjects with Type 2 Diabetes Mellitus", <i>J. Clin. Endocrinol. & Metabol.</i> , 85:4053-4059 (2000) |
| <i>NG</i> | C30 | Smith, R. A., "Optimization of the 4-Aryl Group of 4-Aryl-pyridine Glucagon Antagonists: Development of an Efficient, Alternative Synthesis", <i>Bioorganic & Medicinal Chem. Ltrs.</i> , 12:1303-1306 (2002) |
| <i>NG</i> | C31 | Terleckyj, I., et al., "The Glucagon Receptor Antagonist ALT 3000 Lowers Fasting Hyperglycemia in Rat Models of Diabetes", <i>Diabetes</i> , 45:220A (1996) |
| <i>NG</i> | C32 | Unger, R. H., & Orci, L., "Glucagon", <i>Joslin's Diabetes Mellitus</i> , Chapt. 9:163-176 (1994) |
| <i>NG</i> | C33 | Unger, R. H., "Glucagon physiology and pathophysiology in the light of new advances", <i>Diabetologia</i> , 28:574-578 (1985) |
| <i>NP</i> | C34 | Unger, R. H., "Role of Glucagon in the Pathogenesis of Diabetes: The Status of the Controversy", <i>Metabolism</i> , 27(11):1691-1709 (1978) |
| <i>NG</i> | C35 | Unger, R. H., "THE ESSENTIAL ROLE OF GLUCAGON IN THE PATHOGENESIS OF DIABETES MELLITUS", <i>Lancet</i> , 1:14-16 (1975) |
| <i>NG</i> | C36 | Unson, C. G., et al., "Biological Activities of des-His ¹ [Glu ²]Glucagon Amide, a Glucagon Antagonist", <i>Peptides</i> , 10:1171177 (1989) |
| <i>NG</i> | C37 | Unson, C. G., et al., "Multiple-site Replacement Analogs of Glucagon", <i>Journ. of Biol. Chem.</i> , 269(17):12548-12551 (1994) |
| <i>NG</i> | C38 | Walker et al., <i>Am. J. Physiol.</i> 262(Endocrinol. Metab. 25):E110-E117 (1992) |
| <i>NG</i> | C39 | Wright, L. M., et al., "Structure of Fab hGR-2 F6, a competitive antagonist of the glucagon receptor", <i>Acta Cryst.</i> , D56:573-580 (2000) |
| | C40 | Zieze, B. Y., et al., "[des-His ¹ -des-Phe ⁶ -Glu ²]GLUCAGON-AMIDE: A NEWLY DESIGNED "PURE" GLUCAGON ANTAGONIST", <i>Bioorganic & Medic. Chem. Ltrs.</i> , 5(16):1849-1852 (1995) |

EXAMINER

DATE CONSIDERED

5/16/05

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)

Avail
Not

Q-0-0